| Patient | Gwen Ifill |
|---|---|
| Date of birth | 1965-09-29 |
| Identifiers | MRN HR-ML032-SYN; SSN (made up) 000-32-5814 |
| Document date | 2026-11-01 |
| Author | Lorna Achebe-Price, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review booked. Concerns: Spotting, then light bleeding on and off for about three weeks, eight years after her periods stopped; no pain; She does not want a wait-and-see answer: she knows that bleeding after menopause is sometimes put down to nothing, and she wants the cause found quickly and told plainly; She wants to keep working and to decide who is told. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-02-03 to 2026-02-17 | completed | S |
| Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 2026-02-24 to 2026-06-09 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 2026-02-24 to 2026-06-30 | completed | S |
| Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three years | Every 6 weeks | Intravenous route | 2026-06-30 | active | S |
| Levothyroxine 75 mcg oral tablet, one tablet daily before breakfast | One tablet daily before breakfast | Oral route | 2026-06-30 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Office endometrial biopsy with a suction catheter (Pipelle), with a chaperone, after verbal consent: adequate tissue obtained; tolerated with mild cramping | 2026-01-05 to 2026-01-05 | completed | S |
| Transvaginal ultrasound of the pelvis: endometrium 16 mm, heterogeneous, with an irregular junction with the myometrium and internal blood flow; two small intramural fibroids (1.8 cm and 1.2 cm); ovaries normal for age; no free fluid | 2026-01-07 to 2026-01-07 | completed | S |
| CT of the chest, abdomen and pelvis with contrast: enlarged, heterogeneous uterine cavity; a 1.5 cm right external iliac lymph node and a 1.7 cm left para-aortic lymph node below the renal veins, both suspicious; no liver, lung, bone or peritoneal lesion; no ascites | 2026-01-13 to 2026-01-13 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-08-11 to 2026-08-11 | completed | S |
| Screening mammogram, both breasts | 2026-08-25 to 2026-08-25 | completed | S |
| Robotic-assisted total laparoscopic hysterectomy with removal of both fallopian tubes and ovaries and pelvic washings. Pathology: endometrioid adenocarcinoma, FIGO grade 2 (low grade), 4.2 cm, invading 65% of the myometrial thickness; no cervical stromal invasion; focal (not substantial) lymphovascular space invasion; tubes, ovaries and serosa free; washings negative. Mismatch repair deficient (loss of MLH1 and PMS2), MLH1 promoter hypermethylated, POLE wild-type, p53 wild-type; estrogen receptor positive. FIGO 2023 stage IIIC2ii, molecular class MMRd | 2026-02-03 to 2026-02-03 | completed | S |
| Sentinel lymph node mapping with indocyanine green, both sides of the pelvis: right external iliac sentinel node with a 9 mm metastasis; left obturator sentinel node negative on ultrastaging | 2026-02-03 to 2026-02-03 | completed | S |
| Excision of the enlarged left para-aortic lymph node seen on CT, with adjacent para-aortic nodes below the renal veins: 1 of 4 nodes involved (14 mm deposit) | 2026-02-03 to 2026-02-03 | completed | S |
| Genetic counseling: universal Lynch syndrome tumor screening explained; MLH1 and PMS2 loss explained by MLH1 promoter hypermethylation, which is acquired in the tumor and not inherited; germline testing not indicated; she was told what would change that advice | 2026-02-24 to 2026-02-24 | completed | S |
| CT of the chest, abdomen and pelvis with contrast at the end of combination treatment: no enlarged pelvic or para-aortic lymph node, no vaginal cuff mass, no liver, lung, bone or peritoneal lesion; expected postoperative changes (no evidence of disease) | 2026-06-23 to 2026-06-23 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-08-11 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-08-11 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 2026-08-11 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Spotting, then light bleeding on and off for about three weeks, eight years after her periods stopped; no pain | active | S |
| She does not want a wait-and-see answer: she knows that bleeding after menopause is sometimes put down to nothing, and she wants the cause found quickly and told plainly | active | S |
| She wants to keep working and to decide who is told | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 11.4 on 2026-06-30; Leukocytes [#/volume] in Blood by Automated count 4.9 on 2026-06-30; Platelets [#/volume] in Blood by Automated count 228 on 2026-06-30; Creatinine [Mass/volume] in Serum or Plasma 0.84 on 2026-06-30; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 80 on 2026-06-30; Glucose [Mass/volume] in Serum or Plasma 93 on 2026-08-11; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-01-05; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-08-11; Neutrophils [#/volume] in Blood by Automated count 2.8 on 2026-06-30; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-01-20; Potassium [Moles/volume] in Serum or Plasma 4.3 on 2026-01-20; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 2026-08-11; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 2026-06-30; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 2026-06-30; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-02-24; Cancer Ag 125 [Units/volume] in Serum or Plasma 28 on 2026-01-20; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 2026-06-30; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 7 on 2026-01-20; Magnesium [Mass/volume] in Serum or Plasma 1.8 on 2026-04-28; Thyrotropin [Units/volume] in Serum or Plasma 3.6 on 2026-08-11; Thyroxine (T4) free [Mass/volume] in Serum or Plasma 1.2 on 2026-08-11; Cortisol [Mass/volume] in Serum or Plasma 13.1 on 2026-06-30; Cholesterol [Mass/volume] in Serum or Plasma 204 on 2026-08-11; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 124 on 2026-08-11; Cholesterol in HDL [Mass/volume] in Serum or Plasma 58 on 2026-08-11; Triglyceride [Mass/volume] in Serum or Plasma 110 on 2026-08-11 [S]
Strengths and supports: Lives alone in Washington, D.C.; has no children. Supports: a large extended family she is close to, many friends, and her church community [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | resolved | confirmed | N95.0 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation. |
| Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer | active | confirmed | C54.1 | S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public. |
| Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2023 stage IIIC2ii | active | confirmed | C77.8 | S — Synthetic nodal disease found at surgical staging. |
| Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities) | active | confirmed | G62.0 | S — Synthetic common effect of paclitaxel. |
| Immune-related primary hypothyroidism from dostarlimab: TSH 11.8 with a low free T4, tiredness and feeling cold (grade 2) | active | confirmed | E03.2 | S — Synthetic immune-related adverse event, among the most common with PD-1 inhibitors. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-01-05 | Hemoglobin [Mass/volume] in Blood | 11.8 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-01-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-01-05 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-01-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.82 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-01-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 82 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-05 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-01-05 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2026-01-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-01-20 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-01-20 | Leukocytes [#/volume] in Blood by Automated count | 6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-01-20 | Neutrophils [#/volume] in Blood by Automated count | 3.6 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-01-20 | Platelets [#/volume] in Blood by Automated count | 274 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-01-20 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-01-20 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-01-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-01-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-01-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-35 U/L | Normal | S |
| 2026-01-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 8-35 U/L | Normal | S |
| 2026-01-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-01-20 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-01-20 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 28 | U/mL | <=35 U/mL | Normal | S |
| 2026-01-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 2026-01-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 2026-02-24 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-02-24 | Leukocytes [#/volume] in Blood by Automated count | 6.4 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-02-24 | Neutrophils [#/volume] in Blood by Automated count | 3.9 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-02-24 | Platelets [#/volume] in Blood by Automated count | 301 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-02-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-02-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 87 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-24 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-02-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 2026-02-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 8-35 U/L | Normal | S |
| 2026-02-24 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-02-24 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-02-24 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-02-24 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-02-24 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-02-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-04-28 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-04-28 | Leukocytes [#/volume] in Blood by Automated count | 4.3 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-04-28 | Neutrophils [#/volume] in Blood by Automated count | 2.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-04-28 | Platelets [#/volume] in Blood by Automated count | 196 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-28 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-04-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 83 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-28 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 2026-04-28 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-35 U/L | Normal | S |
| 2026-04-28 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-28 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-04-28 | Thyrotropin [Units/volume] in Serum or Plasma | 4.8 | m[IU]/L | 0.4-4.5 mIU/L | High | S |
| 2026-04-28 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-04-28 | Cortisol [Mass/volume] in Serum or Plasma | 12.6 | ug/dL | Morning sample, drawn before 9 a.m. | Normal | S |
| 2026-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-06-30 | Hemoglobin [Mass/volume] in Blood | 11.4 | g/dL | 12-15.5 g/dL | Low | S |
| 2026-06-30 | Leukocytes [#/volume] in Blood by Automated count | 4.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-06-30 | Neutrophils [#/volume] in Blood by Automated count | 2.8 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-06-30 | Platelets [#/volume] in Blood by Automated count | 228 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-30 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-30 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 2026-06-30 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-35 U/L | Normal | S |
| 2026-06-30 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-06-30 | Thyrotropin [Units/volume] in Serum or Plasma | 11.8 | m[IU]/L | 0.4-4.5 mIU/L | High | S |
| 2026-06-30 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 0.7 | ng/dL | 0.8-1.8 ng/dL | Low | S |
| 2026-06-30 | Cortisol [Mass/volume] in Serum or Plasma | 13.1 | ug/dL | Morning sample, drawn before 9 a.m. | Normal | S |
| 2026-06-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-08-11 | Thyrotropin [Units/volume] in Serum or Plasma | 3.6 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-08-11 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.2 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-08-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 2026-08-11 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-08-11 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=199 mg/dL | High | S |
| 2026-08-11 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 124 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-08-11 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 58 | mg/dL | >=50 mg/dL | Normal | S |
| 2026-08-11 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-08-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-01-05 | Body height | 165 | cm | S |
| 2026-01-05 | Body weight | 74.6 | kg | S |
| 2026-01-05 | Body mass index (BMI) [Ratio] | 27.4 | kg/m2 | S |
| 2026-01-05 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-01-05 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-01-05 | Heart rate | 78 | /min | S |
| 2026-01-05 | Respiratory rate | 16 | /min | S |
| 2026-01-05 | Body temperature | 36.7 | Cel | S |
| 2026-01-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-01-20 | Body height | 165 | cm | S |
| 2026-01-20 | Body weight | 74.2 | kg | S |
| 2026-01-20 | Body mass index (BMI) [Ratio] | 27.3 | kg/m2 | S |
| 2026-01-20 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-01-20 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-01-20 | Heart rate | 84 | /min | S |
| 2026-01-20 | Respiratory rate | 16 | /min | S |
| 2026-01-20 | Body temperature | 36.6 | Cel | S |
| 2026-01-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-02-24 | Body height | 165 | cm | S |
| 2026-02-24 | Body weight | 72.6 | kg | S |
| 2026-02-24 | Body mass index (BMI) [Ratio] | 26.7 | kg/m2 | S |
| 2026-02-24 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-02-24 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-02-24 | Heart rate | 80 | /min | S |
| 2026-02-24 | Respiratory rate | 16 | /min | S |
| 2026-02-24 | Body temperature | 36.7 | Cel | S |
| 2026-02-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-04-28 | Body height | 165 | cm | S |
| 2026-04-28 | Body weight | 71.8 | kg | S |
| 2026-04-28 | Body mass index (BMI) [Ratio] | 26.4 | kg/m2 | S |
| 2026-04-28 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-04-28 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-28 | Heart rate | 82 | /min | S |
| 2026-04-28 | Respiratory rate | 16 | /min | S |
| 2026-04-28 | Body temperature | 36.6 | Cel | S |
| 2026-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 2026-06-30 | Body height | 165 | cm | S |
| 2026-06-30 | Body weight | 72.4 | kg | S |
| 2026-06-30 | Body mass index (BMI) [Ratio] | 26.6 | kg/m2 | S |
| 2026-06-30 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-06-30 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-30 | Heart rate | 64 | /min | S |
| 2026-06-30 | Respiratory rate | 16 | /min | S |
| 2026-06-30 | Body temperature | 36.4 | Cel | S |
| 2026-06-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-08-11 | Body height | 165 | cm | S |
| 2026-08-11 | Body weight | 73 | kg | S |
| 2026-08-11 | Body mass index (BMI) [Ratio] | 26.8 | kg/m2 | S |
| 2026-08-11 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-08-11 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-08-11 | Heart rate | 70 | /min | S |
| 2026-08-11 | Respiratory rate | 16 | /min | S |
| 2026-08-11 | Body temperature | 36.6 | Cel | S |
| 2026-08-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-01-05 | Three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review booked | finished | S |
| 2026-01-20 | Biopsy result: endometrial cancer; staging CT, gynecologic oncology consultation, Lynch syndrome tumor screening, and preparation for surgery | finished | S |
| 2026-02-24 | Review three weeks after surgical staging: final pathology and molecular class, genetic counseling, and the first cycle of dostarlimab with carboplatin and paclitaxel | finished | S |
| 2026-04-28 | Midpoint of combination treatment: blood counts, immune-related adverse event checks, neuropathy, and mood | finished | S |
| 2026-06-30 | End of combination treatment: response CT, immune-related hypothyroidism, the first maintenance dostarlimab dose, and the survivorship plan | finished | S |
| 2026-08-11 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Gynecologic oncology consultation within two weeks to review the endometrial biopsy and ultrasound with her and plan treatment if cancer or atypical hyperplasia is found | completed | GL-NCCN-UTERINE-2026, GL-ACOG-PMB-2026 | S |
| Any bleeding after menopause is evaluated: speculum and bimanual examination, office endometrial biopsy at the first visit, and transvaginal ultrasound within the week, both done rather than relying on endometrial thickness alone; blood count and A1c; results by telephone within days, not at a routine visit | completed | GL-ACOG-PMB-2026, GL-ACOG-CO734-2018, GL-DOLL-2020, GL-CLARKE-2022 | S |
| Staging and molecular classification: CT of the chest, abdomen and pelvis; mismatch repair immunohistochemistry and p53 on the biopsy, with MLH1 promoter methylation testing for MLH1 loss and POLE sequencing on the surgical specimen; FIGO 2023 stage with the molecular class recorded | completed | GL-NCCN-UTERINE-2026, GL-FIGO-2023, GL-CMID-2026 | S |
| Robotic-assisted total laparoscopic hysterectomy with removal of both tubes and ovaries, pelvic washings, sentinel lymph node mapping with indocyanine green, and removal of the enlarged pelvic and para-aortic nodes | completed | GL-NCCN-UTERINE-2026 | S |
| Lynch syndrome screening of the tumor for every endometrial cancer, with genetic counseling; germline testing if mismatch repair loss is not explained by MLH1 promoter methylation, and cascade testing offered to blood relatives only if a germline variant is found | completed | GL-NCCN-UTERINE-2026, GL-ACOG-PB147, GL-CMID-2026 | S |
| Dostarlimab 500 mg with carboplatin (AUC 5) and paclitaxel 175 mg/m2 every three weeks for six cycles, then dostarlimab 1000 mg every six weeks for up to three years, for mismatch repair deficient stage IIIC2 disease; hepatitis B, hepatitis C and HIV screening first; three-drug antiemetic prevention; blood counts, kidney function and magnesium before each cycle; TSH, free T4, liver tests, glucose and morning cortisol at baseline and before each cycle; neuropathy checks at each visit | completed | GL-NCCN-UTERINE-2026, GL-RUBY-2023, GL-JEMPERLI-LABEL, GL-ASCO-IRAE-2021, GL-ASCO-ANTIEMETIC-2020, GL-ASCO-CIPN-2020, GL-ASCO-HBV-2020, GL-CMID-2026 | S |
| Immune-related hypothyroidism: levothyroxine with TSH and free T4 every six weeks, continuing dostarlimab | completed | GL-ASCO-IRAE-2021, GL-JEMPERLI-LABEL, GL-CMID-2026 | S |
| Survivorship: examination with a pelvic examination every three months for two years, CT of the chest, abdomen and pelvis every six months for three years, no routine vaginal cytology and no CA-125 (normal at diagnosis), teaching on symptoms of recurrence, lymphedema checks, sexual health, weight, activity, blood pressure, lipid and glucose care, distress screening, and age-appropriate screening for other cancers | completed | GL-SGO-SURV-2026, GL-NCCN-UTERINE-2026, GL-CMID-2026 | S |
| Distress and depression screening at each visit, plain explanations, written information, and support she chooses; she decides who receives each note | completed | GL-USPSTF-DEP-2023, GL-NCCN-UTERINE-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation | 2026-01-20 | completed | Biopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks | S |
| Surgical staging within four weeks of diagnosis | 2026-02-24 | completed | Minimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultation | S |
| Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week | 2026-06-30 | completed | Six cycles on schedule; CT shows no evidence of disease | S |
| Lynch syndrome tumor screening completed and explained before treatment starts | 2026-02-24 | completed | MLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling done | S |
| Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule | 2026-06-30 | completed | Hypothyroidism found on a scheduled TSH and treated without stopping dostarlimab; one missed baseline cortisol recorded and corrected | S |
| PHQ-9 below 10 throughout treatment, with support she chooses | 2026-06-30 | completed | PHQ-9 between 4 and 6 | S |